Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | XmAb22841 |
| Trade Name | |
| Synonyms | Pavunalimab |
| Drug Descriptions |
Pavunalimab (XmAb22841), is a bispecific antibody that targets CTLA4 and LAG3, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary). |
| DrugClasses | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 150 LAG3 Antibody 19 |
| CAS Registry Number | 2329669-78-3 |
| NCIT ID | C159530 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Izuralimab + XmAb22841 | Izuralimab XmAb22841 | 0 | 1 |
| Pembrolizumab + XmAb22841 | Pembrolizumab XmAb22841 | 0 | 1 |
| XmAb22841 | XmAb22841 | 0 | 1 |